Atlas Unveils A New $450M Fund Targeted At Biotechs
Atlas unveils a new $450M fund targeted at biotechs 2 years after its last
jwaldron
Thu, 12/05/2024 - 08:14.:
Massachusetts-based VC shop Atlas Venture has drawn together another $450 million fund to be channeled toward innovative biotechs. The firm’s fourteenth fund is the same amount to the cent as Atlas’ thirteenth fund back in March 2022. The firm has been busy since then, launching 16 new biotechs and recruiting “approximately 100 executive leaders across its portfolio” in the past two years, it explained in a Dec. 5 release.
Former Fda Leader Launches $70M Biotech Fund
Jupiter takes off with $70M fund for cancer biotechs
gmasson
Tue, 11/19/2024 - 12:47.:
Venture capital fund Jupiter Bioventures is taking off with $70 million for a portfolio of cancer-adjacent biotech startups, or what Jupiter has dubbed its system of “moons.” The company’s founders, Mission BioCapital and Mayo Clinic, are joined by an investor galaxy that includes Alexandria Venture Investments and Bioventure Partners, among others, according to a Nov. 19 release. The $70 million will be shuttled across eight to 10 companies developing cancer therapeutics or working in other disease spaces that benefit from cancer biology insights.
Kurma Closes First $154M Haul For Biggest Biotech Fund Yet
European VC firm Kurma closes first $154M of largest planned fund, eyes up to 20 biotech investments
jwaldron
Thu, 10/03/2024 - 07:12.
Frazier Life Sciences Gathers $630M For Small, Mid-cap Biotechs
Frazier Life Sciences adds $630M to 'evergreen' fund for small and mid-cap biotechs
jwaldron
Wed, 10/02/2024 - 08:50.:
Frazier Life Sciences has sourced a further $630 million for its fund focused on small and mid-cap biotechs. The latest haul of capital commitments from both new and existing investors brings the total raised by the Californian investment firm’s public fund to around $1.7 billion since the fund was set up three years ago.
Biotech Public Markets Finally Thawing(?): Two Massachusetts Biotechs File S-1s | Foley Hoag Llp - Public Companies & The Law
In an encouraging sign that the equity capital markets may be improving for biotechnology companies, Bicara Therapeutics Inc. and Zenas Biopharma, Inc. filed S-1 registration statements yesterday, signaling their intention to complete initial public offerings. Both underwriting syndicates are being led by Morgan Stanley. If successful, they would be the third and fourth Massachusetts biotech IPOs in 2024....By: Foley Hoag LLP - Public Companies & the Law.
Curie.bio Fuels Up With $380M For Biotech Founders
Alexis Borisy-founded VC raises $380M for early-stage biotechs
gmasson
Wed, 06/26/2024 - 10:20.:
Venture capital firm Curie.Bio has fueled up, raising $380 million for biotech founders and promising to stretch the runway of seed money for better long-term results. The latest haul follows a $520 million initial fund and brings Curie.Bio’s total to nearly $1 billion, according to a June 26 release. The funds are expected to go toward series A rounds that support clinical proof-of-concept studies.
J.p. Morgan Arm Secures $500m+ For First Biotech-only Fund
J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund
gmasson
Fri, 06/14/2024 - 10:23.:
J.P. Morgan Private Capital has closed an inaugural life sciences fund of more than $500 million, cash that will go toward a wide range of private biotechs and build value for existing portfolio companies. Dubbed the “270 Life Sciences Private Capital Fund I,” the money was raised in just over a year, Stephen Squinto, Ph.D., chief investment officer and managing partner of J.P. Morgan Life Sciences Private Capital, said in a June 13 release.
Foresite Raises $900M To Make Fresh Set Of Big Biotech Bets
Foresite raises $900M to make big bets in 'one of the best biotech investment environments'
ntaylor
Wed, 06/12/2024 - 03:43.:
Foresite Capital CEO Jim Tananbaum, M.D., says we’re in “one of the best biotech investment environments” of his multidecade career—and has rounded up $900 million to put that belief to the test with a fresh set of big bets. The cash makes up Foresite’s new fund, the sixth raised since Tananbaum founded the VC shop in 2011.
Canada Vc Amplitude Unveils $192M Biotech Fund
Repare backer Amplitude Ventures unveils $192M biotech fund
gmasson
Wed, 05/29/2024 - 10:10.:
Repare Therapeutics backer Amplitude Ventures has unveiled a second fund, securing $192 million that will be dedicated to the development of new precision medicines. The Canada-based VC will channel the cash toward companies that incorporate both biology and artificial intelligence in drug development. Since 2019, Amplitude has set out to create and build companies, including Repare Therapeutics, which IPO'ed in 2020 and was one of Canada’s largest biotech public market debuts at the time.
Petrochemical Replacement Biotech Startup Raises $5.3B In Funding
Cellugy has developed a platform technology that enables the creation of fully bio-based and biodegradable alternatives to carbon-intensive petrochemicals. :
Danish industrial biotech startup Cellugy has raised $5.3 billion (EUR 4.9 million) in seed funding to scale up production of its technology aiming to replace petrochemicals in cosmetics. The round was led by Germany’s ICIG Ventures and Denmark’s Unconventional Ventures, with new, U.S.-based investor Joyance Partners joining the round, along with existing investors PSV DeepTech, The Footprint Firm, and EIFO, according to a news release from ICIG Ventures.